Seer (SEER) Q4 2024: 24% Revenue Growth Guidance Highlights Transition to Scalable Proteomics Platform
Seer reported a challenging 2024 marked by lower instrument sales and macroeconomic headwinds but strengthened its position with expanding customer validation and strategic partnerships. The company’s shift toward scalable proteomics access through its STAC service and new product innovations underpins a confident outlook with 24% revenue growth guidance for 2025. Execution on commercial expansion and technology innovation remain critical as Seer navigates funding uncertainties and aims to accelerate adoption globally.
Summary
- Validation Momentum: Accelerating customer publications and robust platform differentiation reinforce Seer’s leadership in deep unbiased proteomics.
- Commercial Expansion: Growth driven by STAC services and expanded sales infrastructure despite continued macroeconomic and NIH funding challenges.
- Strategic Outlook: 24% revenue growth guidance for 2025 reflects confidence in platform scalability and emerging partnerships, balanced against funding uncertainties.
Business Overview
Seer is a life sciences company specializing in proteomics, the large-scale study of proteins critical for understanding biology and disease. The company generates revenue primarily through sales of its Proteograph Product Suite, which includes proprietary instruments, consumables, and services such as the SEER Technology Access Center (STAC) that provides proteomic data analysis. Seer’s business is segmented into product sales (instruments and consumables), service revenue (primarily STAC projects), and related party transactions, with a growing installed base of instruments supporting consumable pull-through.
Performance Analysis
Seer reported $4.0 million in revenue for Q4 2024, down 10% year-over-year, reflecting lower instrument sales and the absence of grant revenue. For the full year, revenue declined 15% to $14.2 million, primarily due to the same factors. However, excluding related party and grant revenues, product and service revenues combined increased 11% year-over-year to $11.7 million, signaling underlying growth in core operations. The installed base of instruments stood at 49 by year-end, supporting an annual consumable pull-through of approximately $174,000 per instrument, a key metric indicating customer engagement and recurring revenue potential.
Gross margins improved to 51% in Q4 from 45% a year earlier, driven by a higher mix of consumables and services, although the company expects margin volatility quarter-to-quarter. Operating expenses rose modestly, with R&D increasing 13% due to laboratory investments, while SG&A declined slightly. Net loss widened to $21.7 million in Q4 from $17.8 million, reflecting ongoing investments in growth and innovation. Free cash flow loss narrowed to $49.4 million for 2024 from $66.4 million in 2023, supported by disciplined expense management and share repurchases that reduced shares outstanding by approximately 10%.
- Revenue Dynamics: Instrument sales softness offset by rising consumable and service revenues, highlighting transition to recurring revenue streams.
- Margin Improvement: Shift in revenue mix towards higher-margin consumables and services contributed to gross margin expansion despite sales headwinds.
- Capital Efficiency: Share repurchases and reduced equity dilution reflect confidence in long-term value and prudent capital deployment amid cash burn.
Overall, the financial results illustrate Seer’s pivot from early-stage instrument sales toward a more scalable and recurring revenue model anchored by consumables and STAC services, setting the stage for growth acceleration in 2025.
Executive Commentary
"Our customers have made important progress in validating the differentiated value of deep, unbiased proteomics at scale throughout the year, and I’m thrilled that the momentum is growing despite the challenging macroeconomic environment... I believe we are well-positioned for a stronger year in 2025 and my confidence in our platform, our value proposition, and the immense opportunity ahead has never been greater."
Omid Farokhzad, Chief Executive Officer and Chair of the Board
"We continue to see pressure on CapEx budgets and elongated sales cycles for the outright purchase of new instruments, but service revenue related to STAC projects is growing... Our installed base grew to 49 instruments, supporting a consumable pull-through of approximately $174,000 per instrument annually, which we expect to monitor and grow as we expand adoption."
David Horn, Chief Financial Officer and President
Strategic Positioning
1. Platform Validation and Scientific Leadership
Seer has made significant strides in validating its Proteograph platform through 33 customer publications, including 23 peer-reviewed papers in 2024 alone. Independent academic studies have benchmarked Seer’s technology as superior in depth, reproducibility, and quantitative performance compared to competitors attempting to replicate its nanoparticle-based proteomics. This growing body of evidence is a critical strategic asset, underpinning customer confidence and accelerating adoption across biopharma and academic research.
2. Expanding Access via STAC and Commercial Infrastructure
The SEER Technology Access Center (STAC) has been pivotal in lowering barriers to entry, allowing customers to access proteomic data without upfront instrument purchases. With over 135 customers served globally and a second STAC facility opened in Europe, the service is driving repeat business and facilitating instrument sales through the Strategic Instrument Placement Program (SIP). The doubling of the North American commercial sales team and new partnerships, notably the expanded co-marketing agreement with Thermo Fisher Scientific, bolster Seer’s global reach and pipeline development.
3. Product Innovation and Workflow Enhancements
Seer continues to innovate with the launch of a new Proteograph XT application targeting intracellular proteomics, expanding the platform’s utility beyond plasma and tissue samples. The upgrade of the Proteomic Analysis Suite (PASS) software has dramatically accelerated data processing times by over 95%, enhancing scalability and customer experience. These innovations are expected to unlock new research opportunities and increase the platform’s competitive moat.
4. Financial Discipline and Capital Allocation
Despite operating losses, Seer has demonstrated financial discipline through share repurchases reducing dilution and free cash flow improvement. The company’s strong cash position of approximately $300 million provides runway to invest in growth initiatives while managing cash flow. Management’s decision to forego equity incentive plan refresh and retire shares from RSU vesting further reflects a focus on shareholder value preservation.
5. Navigating Macro and Funding Uncertainties
Seer is contending with constrained capital expenditure budgets among customers and uncertainty around NIH and government funding, which represented about 12% of 2024 revenue. Management has prudently factored these risks into its 2025 guidance and maintains a cautious outlook on academic and government spending, while remaining optimistic about longer-term funding stability and scientific investment trends.
Key Considerations
Seer’s 2024 results and 2025 guidance highlight several critical themes for investors:
- Consumable Pull-Through as Growth Lever: With an installed base of 49 instruments, consumable revenue per instrument is a key recurring revenue driver and indicator of customer engagement.
- STAC’s Role in Adoption: The STAC service model is a strategic enabler, providing low-barrier access that fuels customer validation and eventual instrument purchases.
- Partnership Expansion: The Thermo Fisher co-marketing agreement and ongoing dialogues with other mass spectrometry providers enhance Seer’s commercial reach and technological integration.
- Publication Pipeline Acceleration: Growing customer publications serve as a powerful marketing and validation tool, driving broader awareness and adoption.
- Macro and Funding Risks: NIH budget uncertainties and cautious customer CapEx spending remain headwinds that could delay instrument placements and revenue recognition.
Risks
Seer faces execution risks related to macroeconomic and government funding uncertainties, which could constrain customer budgets and delay instrument sales. The company’s reliance on continued scientific validation and adoption of a novel proteomics platform introduces risk if competitors close performance gaps or if customer demand does not scale as anticipated. Additionally, operating losses and cash burn necessitate prudent capital management to sustain growth initiatives.
Forward Outlook
For 2025, Seer projects revenue between $17 million and $18 million, implying 24% growth at the midpoint over 2024. This guidance incorporates ongoing macroeconomic challenges and NIH funding uncertainty, particularly affecting approximately 30% of revenue derived from government and academic customers. Management expects gross margins to range between 50% and 53%, with continued investments in sales infrastructure and product innovation. Free cash flow loss is forecasted between $40 million and $45 million, reflecting a continued balance between growth and capital discipline.
Takeaways
Seer’s Q4 and full-year 2024 results illustrate a company in transition from early-stage instrument sales toward a scalable, recurring revenue model centered on consumables and services. The expanding installed base and growing customer validation through publications and STAC usage underpin a positive growth trajectory despite persistent macro and funding headwinds.
- Platform Validation Drives Confidence: Independent studies and an increasing publication pipeline reinforce Seer’s technological leadership, a critical factor for adoption in the proteomics market.
- Commercial Execution Accelerates Access: Investments in sales force expansion, global partnerships, and service capacity are key to converting scientific validation into revenue growth.
- Watch for Funding Clarity and Adoption Pace: Investor focus should remain on NIH and government funding developments, instrument placement velocity, and consumable pull-through trends as indicators of Seer’s growth sustainability.
Conclusion
Seer’s fourth quarter and full-year 2024 results reflect both the challenges of a constrained macro environment and the promise of a validated, differentiated proteomics platform. The company’s strategic emphasis on expanding access, driving innovation, and leveraging partnerships positions it well for growth acceleration in 2025, supported by a robust cash position and disciplined capital management.
Industry Read-Through
Seer’s experience underscores broader industry dynamics in proteomics and life sciences research tools, where platform validation and scalable access models are critical to adoption. The growing importance of service-based access, as exemplified by STAC, suggests that other companies may need to innovate beyond traditional instrument sales to drive recurring revenue. Additionally, the impact of government funding uncertainty on research budgets is a common challenge across the sector, highlighting the need for diversified customer bases and flexible commercial strategies.